Details of the Drug

General Information of Drug (ID: DM79NTF)

Drug Name

Propranolol

Synonyms

Anaprilin; Anapriline; Avlocardyl; Bedranol; Berkolol; Betachron; Betadren; Betalong; Caridolol; Corpendol; Dociton; Efektolol; Etalong; Euprovasin; Herzbase; Ikopal; Inderal; Inderalici; Inderex; Inderol; Intermigran; Kemi; Migrastat; Naprilin; Obsidan; Obzidan; Pranolol; Pronovan; Propanalol; Propanix; Propanolol; Propranalol; Propranololo; Propranololum; Proprasylyt; Reducor; Sawatal; Servanolol; Sumial; Beta Neg; Inderal hydrochloride; Kemi S; Propranolol Hcl Intensol; Propranololo [DCIT]; Racemic propranolol; Reducorline; AY 64043; AY-20694; Anaprilinum (TN); Avlocardyl (TN); Beta-Propranolol; Beta-Tablinen; Beta-Timelets; DL-Propranolol hydrochloride; Deralin (TN); Dociton (TN); Inderal (TN); Inderal LA (TN); Inderalici (TN); InnoPran XL (TN); Propanolol [INN-Spanish]; Propranolol (INN); Propranolol (TN); Propranolol [INN:BAN]; Propranololum [INN-Latin]; Sumial (TN); D,L-Propranolol; INDERIDE-40/25; R,S-Propranolol Hydrochloride; (+-)-Propranolol; (1)-1-(Isopropylamino)-3-(naphthyloxy)propan-2-ol; (R)-(+)-propranolol; (S)-(-)-PROPRANOLOL; 1-((1-Methylethyl)amino)-3-(1-naphthalenyloxy)-2-propanol; 1-(1-Naphthyloxy)-2-hydroxy-3-(isopropylamino)propane; 1-(Isopropylamino)-3-(1-naphthoxy)-propan-2-ol; 1-(Isopropylamino)-3-(1-naphthyloxy)-2-propanol; 1-(isopropylamino)-3-(1-naphthyloxy)propan-2-ol; 1-(naphthalen-1-yloxy)-3-(propan-2-ylamino)propan-2-ol; 1-Isopropylamino-3-(1-naphthyloxy)-2-propanol; 1-[(1-methylethyl)amino]-3-(naphthalen-1-yloxy)propan-2-ol; 1-naphthalen-1-yloxy-3-(propan-2-ylamino)propan-2-ol; 2-Propanol, 1-((1-methylethyl)amino)-3-(1-naphthalenyloxy)-(9CI); 2-Propanol, 1-((1-methylethyl)amino)-3-(1-naphthalenyloxy)-, (+-)-(9CI); 3-(naphthalen-1-yloxy)-1-(propan-2-ylamino)propan-2-ol

Indication

Disease Entry	ICD 11	Status	REF
Angina pectoris	BA40	Approved	[1]
Atrial fibrillation	BC81.3	Approved	[1]
Cocaine addiction	6C45.2	Approved	[1]
Hemangioma	2E81-2F2Y	Approved	[1]
Migraine	8A80	Approved	[2]
Respiratory papillomatosis	2F00.1	Investigative	[1]
------------------------------------------------------------------------------------


⏷ Show the Full List of Indication(s)

Therapeutic Class

Antianxiety Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

259.339

Logarithm of the Partition Coefficient (xlogp)

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Absorption Cmax: The maximum plasma concentration (Cmax) of drug is 18 +/- 15 mcg/L [3]
Absorption Tmax: The time to maximum plasma concentration (Tmax) is 2 h [3]
BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [4]
Clearance: The clearance of drug is 2.7 +/- 0.03 L/h/kg [5]
Elimination: 91% of an oral dose of propranolol is recovered as 12 metabolites in the urine [6]
Half-life: The concentration or amount of drug in body reduced by one-half in 8 hours [7]
Metabolism: The drug is metabolized via side chain oxidation to -naphthoxylactic acid []
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 35.2529 micromolar/kg/day [8]
Unbound Fraction: The unbound fraction of drug in plasma is 0.13% [9]
Vd: The volume of distribution (Vd) of drug is 4 L/kg or 320 L [3]
Water Solubility: The ability of drug to dissolve in water is measured as 50 mg/mL [4]

Adverse Drug Reaction (ADR)

ADR Term	Variation	Related DOT	DOT ID	REF
Poisoning and toxicity	Not Available	CYP1A1	OTE4EFH8	[10]
Sudden cardiac death	Not Available	SCN5A	OTGYZWR6	[10]
Sudden cardiac death	Not Available	KCNE1	OTZNQUW9	[10]
-----------

Chemical Identifiers

Formula: C16H21NO2
IUPAC Name: 1-naphthalen-1-yloxy-3-(propan-2-ylamino)propan-2-ol
Canonical SMILES: CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O
InChI: InChI=1S/C16H21NO2/c1-12(2)17-10-14(18)11-19-16-9-5-7-13-6-3-4-8-15(13)16/h3-9,12,14,17-18H,10-11H2,1-2H3
InChIKey: AQHHHDLHHXJYJD-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 4946
ChEBI ID: CHEBI:8499
CAS Number: 525-66-6
DrugBank ID: DB00571
TTD ID: D04JEE
VARIDT ID: DR00528
INTEDE ID: DR1367
ACDINA ID: D00565

Combinatorial Drugs (CBD)

Click to Jump to the Detailed CBD Information of This Drug

Repurposed Drugs (RPD)

Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Adrenergic receptor beta-1 (ADRB1)	TTR6W5O	ADRB1_HUMAN	Antagonist	[11]

------------------------------------------------------------------------------------

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Organic cation transporter 3 (SLC22A3)	DT6201N	S22A3_HUMAN	Substrate	[12]
Organic cation transporter 1 (SLC22A1)	DTT79CX	S22A1_HUMAN	Substrate	[12]
Organic cation transporter 2 (SLC22A2)	DT9IDPW	S22A2_HUMAN	Substrate	[12]
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[13]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Substrate	[14]
Cytochrome P450 2D6 (CYP2D6)	DECB0K3	CP2D6_HUMAN	Substrate	[15]
Mephenytoin 4-hydroxylase (CYP2C19)	DEGTFWK	CP2CJ_HUMAN	Substrate	[16]
Cytochrome P450 1A2 (CYP1A2)	DEJGDUW	CP1A2_HUMAN	Substrate	[17]
Cytochrome P450 3A5 (CYP3A5)	DEIBDNY	CP3A5_HUMAN	Substrate	[18]
Cytochrome P450 3A7 (CYP3A7)	DERD86B	CP3A7_HUMAN	Substrate	[18]
Dimethylaniline oxidase 2 (FMO2)	DEIASEZ	FMO2_HUMAN	Substrate	[19]
Cytochrome P450 102A1 (cyp102)	DE4OGUF	CPXB_BACMB	Substrate	[20]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
72 kDa type IV collagenase (MMP2)	OT5NIWA2	MMP2_HUMAN	Gene/Protein Processing	[21]
ADP-ribosylation factor 6 (ARF6)	OTVV7KJO	ARF6_HUMAN	Protein Interaction/Cellular Processes	[22]
Angiopoietin-1 receptor (TEK)	OT78YN57	TIE2_HUMAN	Gene/Protein Processing	[23]
Angiopoietin-2 (ANGPT2)	OTEQK65P	ANGP2_HUMAN	Gene/Protein Processing	[23]
Angiotensinogen (AGT)	OTBZLYR3	ANGT_HUMAN	Gene/Protein Processing	[24]
Apoptosis regulator BAX (BAX)	OTAW0V4V	BAX_HUMAN	Gene/Protein Processing	[23]
Apoptosis regulator Bcl-2 (BCL2)	OT9DVHC0	BCL2_HUMAN	Gene/Protein Processing	[23]
ATP-dependent translocase ABCB1 (ABCB1)	OTEJROBO	MDR1_HUMAN	Gene/Protein Processing	[25]
Beta-2 adrenergic receptor (ADRB2)	OTSDOX4Q	ADRB2_HUMAN	Gene/Protein Processing	[26]
Beta-adrenergic receptor kinase 1 (GRK2)	OT34KKWK	ARBK1_HUMAN	Gene/Protein Processing	[27]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Propranolol

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Rizatriptan	DMDJMA3	Moderate	Decreased metabolism of Propranolol caused by Rizatriptan mediated inhibition of non-CYP450 enzyme.	Migraine [8A80]	[28]
-----------

Coadministration of a Drug Treating the Disease Different from Propranolol (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Arn-509	DMT81LZ	Moderate	Increased metabolism of Propranolol caused by Arn-509 mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[29]
Scopolamine	DMOM8AL	Moderate	Antagonize the effect of Propranolol when combined with Scopolamine.	Addictive disorder [6C50-6C5Z]	[30]
Bepridil	DM0RKS4	Moderate	Increased risk of cardiac depression by the combination of Propranolol and Bepridil.	Angina pectoris [BA40]	[31]
Nifedipine	DMSVOZT	Moderate	Increased risk of cardiac depression by the combination of Propranolol and Nifedipine.	Angina pectoris [BA40]	[31]
Methylphenobarbital	DMDSWAG	Moderate	Increased metabolism of Propranolol caused by Methylphenobarbital mediated induction of CYP450 enzyme.	Anxiety disorder [6B00-6B0Z]	[32]
Oxazepam	DMXNZM4	Minor	Decreased metabolism of Propranolol caused by Oxazepam.	Anxiety disorder [6B00-6B0Z]	[33]
Voriconazole	DMAOL2S	Moderate	Decreased metabolism of Propranolol caused by Voriconazole mediated inhibition of CYP450 enzyme.	Aspergillosis [1F20]	[30]
Zileuton	DMVRIC2	Moderate	Decreased metabolism of Propranolol caused by Zileuton.	Asthma [CA23]	[34]
Obeticholic acid	DM3Q1SM	Moderate	Decreased metabolism of Propranolol caused by Obeticholic acid mediated inhibition of CYP450 enzyme.	Autoimmune liver disease [DB96]	[35]
Cariprazine	DMJYDVK	Moderate	Additive hypotensive effects by the combination of Propranolol and Cariprazine.	Bipolar disorder [6A60]	[36]
Atracurium	DM42HXN	Moderate	Additive cardiorespiratory depression effects by the combination of Propranolol and Atracurium.	Corneal disease [9A76-9A78]	[37]
Mivacurium	DM473VD	Moderate	Additive cardiorespiratory depression effects by the combination of Propranolol and Mivacurium.	Corneal disease [9A76-9A78]	[37]
Pancuronium	DMB0VY8	Moderate	Additive cardiorespiratory depression effects by the combination of Propranolol and Pancuronium.	Corneal disease [9A76-9A78]	[37]
Tubocurarine	DMBZIVP	Moderate	Additive neuromuscular blocking effects by the combination of Propranolol and Tubocurarine.	Corneal disease [9A76-9A78]	[37]
Pasireotide	DMHM7JS	Moderate	Increased risk of bradycardia by the combination of Propranolol and Pasireotide.	Cushing syndrome [5A70]	[38]
Osilodrostat	DMIJC9X	Moderate	Decreased metabolism of Propranolol caused by Osilodrostat mediated inhibition of CYP450 enzyme.	Cushing syndrome [5A70]	[39]
MK-8228	DMOB58Q	Moderate	Increased metabolism of Propranolol caused by MK-8228 mediated induction of CYP450 enzyme.	Cytomegaloviral disease [1D82]	[40]
Sertraline	DM0FB1J	Moderate	Decreased metabolism of Propranolol caused by Sertraline mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[41]
Paroxetine	DM5PVQE	Moderate	Decreased metabolism of Propranolol caused by Paroxetine mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[41]
OPC-34712	DMHG57U	Moderate	Additive hypotensive effects by the combination of Propranolol and OPC-34712.	Depression [6A70-6A7Z]	[36]
Maprotiline	DMPWB7T	Minor	Decreased metabolism of Propranolol caused by Maprotiline.	Depression [6A70-6A7Z]	[42]
Mepenzolate	DM8YU2F	Moderate	Antagonize the effect of Propranolol when combined with Mepenzolate.	Digestive system disease [DE2Z]	[30]
Oxybutynine	DMJPBAX	Moderate	Antagonize the effect of Propranolol when combined with Oxybutynine.	Discovery agent [N.A.]	[29]
Diazepam	DM08E9O	Minor	Decreased metabolism of Propranolol caused by Diazepam.	Epilepsy/seizure [8A61-8A6Z]	[33]
Primidone	DM0WX6I	Moderate	Increased metabolism of Propranolol caused by Primidone mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[43]
Oxcarbazepine	DM5PU6O	Moderate	Decreased metabolism of Propranolol caused by Oxcarbazepine mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[30]
Cenobamate	DM8KLU9	Moderate	Decreased metabolism of Propranolol caused by Cenobamate mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[44]
Stiripentol	DMMSDOY	Moderate	Decreased metabolism of Propranolol caused by Stiripentol mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[45]
Brivaracetam	DMSEPK8	Minor	Decreased metabolism of Propranolol caused by Brivaracetam mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[29]
Phenobarbital	DMXZOCG	Moderate	Increased metabolism of Propranolol caused by Phenobarbital mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[43]
Ethacrynic acid	DM60QMR	Moderate	Increased risk of hypertriglyceridemia by the combination of Propranolol and Ethacrynic acid.	Essential hypertension [BA00]	[46]
Phenoxybenzamine	DM8KSQH	Moderate	Additive hypotensive effects by the combination of Propranolol and Phenoxybenzamine.	Essential hypertension [BA00]	[47]
Nicardipine	DMCDYW7	Moderate	Increased risk of cardiac depression by the combination of Propranolol and Nicardipine.	Essential hypertension [BA00]	[31]
Mirabegron	DMS1GYT	Moderate	Decreased metabolism of Propranolol caused by Mirabegron mediated inhibition of CYP450 enzyme.	Functional bladder disorder [GC50]	[48]
Tolterodine	DMSHPW8	Moderate	Antagonize the effect of Propranolol when combined with Tolterodine.	Functional bladder disorder [GC50]	[30]
Terbinafine	DMI6HUW	Moderate	Decreased metabolism of Propranolol caused by Terbinafine mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[49]
Propantheline	DM2EN6G	Moderate	Antagonize the effect of Propranolol when combined with Propantheline.	Gastric ulcer [DA60]	[30]
Chlorothiazide	DMLHESP	Moderate	Increased risk of hyperglycemia by the combination of Propranolol and Chlorothiazide.	Heart failure [BD10-BD1Z]	[46]
Furosemide	DMMQ8ZG	Moderate	Increased risk of hyperglycemia by the combination of Propranolol and Furosemide.	Heart failure [BD10-BD1Z]	[46]
Bumetanide	DMRV7H0	Moderate	Increased risk of hyperglycemia by the combination of Propranolol and Bumetanide.	Heart failure [BD10-BD1Z]	[46]
Hydroflumethiazide	DMVPUQI	Moderate	Increased risk of ventricular arrhythmias by the combination of Propranolol and Hydroflumethiazide.	Heart failure [BD10-BD1Z]	[46]
Rifampin	DMA8J1G	Moderate	Increased metabolism of Propranolol caused by Rifampin mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[50]
Cobicistat	DM6L4H2	Moderate	Decreased metabolism of Propranolol caused by Cobicistat mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[51]
Etravirine	DMGV8QU	Moderate	Decreased metabolism of Propranolol caused by Etravirine mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[52]
Fenofibrate	DMFKXDY	Moderate	Decreased metabolism of Propranolol caused by Fenofibrate mediated inhibition of CYP450 enzyme.	Hyper-lipoproteinaemia [5C80]	[30]
Teriflunomide	DMQ2FKJ	Moderate	Increased metabolism of Propranolol caused by Teriflunomide mediated induction of CYP450 enzyme.	Hyper-lipoproteinaemia [5C80]	[30]
Cinacalcet	DMCX0K3	Moderate	Decreased metabolism of Propranolol caused by Cinacalcet mediated inhibition of CYP450 enzyme.	Hyper-parathyroidism [5A51]	[30]
Levamlodipine	DM92S6N	Moderate	Increased risk of cardiac depression by the combination of Propranolol and Levamlodipine.	Hypertension [BA00-BA04]	[31]
Doxazosin	DM9PLRH	Moderate	Additive hypotensive effects by the combination of Propranolol and Doxazosin.	Hypertension [BA00-BA04]	[47]
Verapamil	DMA7PEW	Major	Increased risk of cardiac depression by the combination of Propranolol and Verapamil.	Hypertension [BA00-BA04]	[31]
Indapamide	DMGN1PW	Moderate	Increased risk of hypertriglyceridemia by the combination of Propranolol and Indapamide.	Hypertension [BA00-BA04]	[46]
Trichlormethiazide	DMHAQCO	Moderate	Increased risk of ventricular arrhythmias by the combination of Propranolol and Trichlormethiazide.	Hypertension [BA00-BA04]	[46]
Felodipine	DMOSW35	Moderate	Increased risk of cardiac depression by the combination of Propranolol and Felodipine.	Hypertension [BA00-BA04]	[31]
Hydralazine	DMU8JGH	Minor	Decreased metabolism of Propranolol caused by Hydralazine mediated interference with first-pass metabolism.	Hypertension [BA00-BA04]	[53]
Hydrochlorothiazide	DMUSZHD	Moderate	Increased risk of hyperglycemia by the combination of Propranolol and Hydrochlorothiazide.	Hypertension [BA00-BA04]	[46]
Clevidipine butyrate	DMW4M97	Moderate	Increased risk of cardiac depression by the combination of Propranolol and Clevidipine butyrate.	Hypertension [BA00-BA04]	[31]
Givosiran	DM5PFIJ	Moderate	Decreased metabolism of Propranolol caused by Givosiran mediated inhibition of CYP450 enzyme.	Inborn porphyrin/heme metabolism error [5C58]	[54]
Belladonna	DM2RBWK	Moderate	Antagonize the effect of Propranolol when combined with Belladonna.	Infectious gastroenteritis/colitis [1A40]	[29]
Berotralstat	DMWA2DZ	Moderate	Decreased metabolism of Propranolol caused by Berotralstat mediated inhibition of CYP450 enzyme.	Innate/adaptive immunodeficiency [4A00]	[55]
Amobarbital	DM0GQ8N	Moderate	Increased metabolism of Propranolol caused by Amobarbital mediated induction of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[43]
Propiomazine	DMKY8V1	Moderate	Additive hypotensive effects by the combination of Propranolol and Propiomazine.	Insomnia [7A00-7A0Z]	[36]
ITI-007	DMUQ1DO	Moderate	Additive hypotensive effects by the combination of Propranolol and ITI-007.	Insomnia [7A00-7A0Z]	[36]
Clidinium	DMUMQZ0	Moderate	Antagonize the effect of Propranolol when combined with Clidinium.	Irritable bowel syndrome [DD91]	[29]
Dicyclomine	DMZSDGX	Moderate	Antagonize the effect of Propranolol when combined with Dicyclomine.	Irritable bowel syndrome [DD91]	[29]
Glycerol phenylbutyrate	DMDGRQO	Moderate	Decreased metabolism of Propranolol caused by Glycerol phenylbutyrate mediated inhibition of CYP450 enzyme.	Liver disease [DB90-DB9Z]	[29]
Dacomitinib	DMOH8VY	Moderate	Decreased metabolism of Propranolol caused by Dacomitinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[56]
Osimertinib	DMRJLAT	Moderate	Increased metabolism of Propranolol caused by Osimertinib mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[57]
Capmatinib	DMYCXKL	Moderate	Decreased metabolism of Propranolol caused by Capmatinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[58]
Lumefantrine	DM29GAD	Moderate	Decreased metabolism of Propranolol caused by Lumefantrine mediated inhibition of CYP450 enzyme.	Malaria [1F40-1F45]	[30]
Chloroquine	DMSI5CB	Minor	Decreased metabolism of Propranolol caused by Chloroquine mediated inhibition of CYP450 enzyme.	Malaria [1F40-1F45]	[59]
Vemurafenib	DM62UG5	Moderate	Decreased metabolism of Propranolol caused by Vemurafenib mediated inhibition of CYP450 enzyme.	Melanoma [2C30]	[60]
Dabrafenib	DMX6OE3	Moderate	Increased metabolism of Propranolol caused by Dabrafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[29]
Ethinyl estradiol	DMODJ40	Moderate	Decreased metabolism of Propranolol caused by Ethinyl estradiol mediated interference with first-pass metabolism.	Menopausal disorder [GA30]	[61]
Lanthanum carbonate	DMMJQSH	Moderate	Decreased absorption of Propranolol due to formation of complexes caused by Lanthanum carbonate.	Mineral absorption/transport disorder [5C64]	[38]
Panobinostat	DM58WKG	Moderate	Decreased metabolism of Propranolol caused by Panobinostat mediated inhibition of CYP450 enzyme.	Multiple myeloma [2A83]	[62]
Thalidomide	DM70BU5	Moderate	Increased risk of ventricular arrhythmias by the combination of Propranolol and Thalidomide.	Multiple myeloma [2A83]	[30]
Siponimod	DM2R86O	Major	Increased risk of atrioventricular block by the combination of Propranolol and Siponimod.	Multiple sclerosis [8A40]	[30]
Fingolimod	DM5JVAN	Major	Increased risk of bradycardia by the combination of Propranolol and Fingolimod.	Multiple sclerosis [8A40]	[63]
Ozanimod	DMT6AM2	Moderate	Increased risk of atrioventricular block by the combination of Propranolol and Ozanimod.	Multiple sclerosis [8A40]	[64]
Fedratinib	DM4ZBK6	Moderate	Decreased metabolism of Propranolol caused by Fedratinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[29]
Nilotinib	DM7HXWT	Moderate	Decreased metabolism of Propranolol caused by Nilotinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[65]
Imatinib	DM7RJXL	Moderate	Decreased metabolism of Propranolol caused by Imatinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[66]
Modafinil	DMYILBE	Moderate	Decreased metabolism of Propranolol caused by Modafinil mediated inhibition of CYP450 enzyme.	Narcolepsy [7A20]	[30]
Promethazine	DM6I5GR	Moderate	Additive hypotensive effects by the combination of Propranolol and Promethazine.	Nausea/vomiting [MD90]	[36]
Rolapitant	DM8XP26	Moderate	Decreased metabolism of Propranolol caused by Rolapitant mediated inhibition of CYP450 enzyme.	Nausea/vomiting [MD90]	[67]
Bupropion	DM5PCS7	Moderate	Decreased metabolism of Propranolol caused by Bupropion mediated inhibition of CYP450 enzyme.	Nicotine use disorder [6C4A]	[68]
Lorcaserin	DMG6OYJ	Moderate	Decreased metabolism of Propranolol caused by Lorcaserin mediated inhibition of CYP450 enzyme.	Obesity [5B80-5B81]	[69]
Polythiazide	DMCH80F	Moderate	Increased risk of hyperglycemia by the combination of Propranolol and Polythiazide.	Oedema [MG29]	[46]
Olaparib	DM8QB1D	Moderate	Increased metabolism of Propranolol caused by Olaparib mediated induction of CYP450 enzyme.	Ovarian cancer [2C73]	[30]
Rucaparib	DM9PVX8	Moderate	Decreased metabolism of Propranolol caused by Rucaparib mediated inhibition of CYP450 enzyme.	Ovarian cancer [2C73]	[70]
Dextropropoxyphene	DM23HCX	Moderate	Decreased metabolism of Propranolol caused by Dextropropoxyphene mediated inhibition of CYP450 enzyme.	Pain [MG30-MG3Z]	[71]
Biperiden	DME78OA	Moderate	Antagonize the effect of Propranolol when combined with Biperiden.	Parkinsonism [8A00]	[30]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Propranolol caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[72]
Methylscopolamine	DM5VWOB	Moderate	Antagonize the effect of Propranolol when combined with Methylscopolamine.	Peptic ulcer [DA61]	[29]
Lonafarnib	DMGM2Z6	Moderate	Decreased metabolism of Propranolol caused by Lonafarnib mediated inhibition of CYP450 enzyme.	Premature ageing appearance [LD2B]	[73]
ABIRATERONE	DM8V75C	Moderate	Decreased metabolism of Propranolol caused by ABIRATERONE mediated inhibition of CYP450 enzyme.	Prostate cancer [2C82]	[74]
Enzalutamide	DMGL19D	Moderate	Increased metabolism of Propranolol caused by Enzalutamide mediated induction of CYP450 enzyme.	Prostate cancer [2C82]	[75]
Terazosin	DM3JCVS	Moderate	Additive hypotensive effects by the combination of Propranolol and Terazosin.	Prostate hyperplasia [GA90]	[47]
Silodosin	DMJSBT6	Moderate	Additive hypotensive effects by the combination of Propranolol and Silodosin.	Prostate hyperplasia [GA90]	[47]
Levomepromazine	DMIKFEL	Moderate	Additive hypotensive effects by the combination of Propranolol and Levomepromazine.	Psychotic disorder [6A20-6A25]	[36]
Fluphenazine	DMIT8LX	Moderate	Additive hypotensive effects by the combination of Propranolol and Fluphenazine.	Psychotic disorder [6A20-6A25]	[36]
Quetiapine	DM1N62C	Moderate	Additive hypotensive effects by the combination of Propranolol and Quetiapine.	Schizophrenia [6A20]	[36]
Mesoridazine	DM2ZGAN	Moderate	Additive hypotensive effects by the combination of Propranolol and Mesoridazine.	Schizophrenia [6A20]	[36]
Thioridazine	DM35M8J	Major	Decreased metabolism of Propranolol caused by Thioridazine mediated inhibition of CYP450 enzyme.	Schizophrenia [6A20]	[76]
Aripiprazole	DM3NUMH	Moderate	Additive hypotensive effects by the combination of Propranolol and Aripiprazole.	Schizophrenia [6A20]	[36]
Iloperidone	DM6AUFY	Moderate	Additive hypotensive effects by the combination of Propranolol and Iloperidone.	Schizophrenia [6A20]	[36]
Paliperidone	DM7NPJS	Moderate	Additive hypotensive effects by the combination of Propranolol and Paliperidone.	Schizophrenia [6A20]	[36]
Perphenazine	DMA4MRX	Moderate	Additive hypotensive effects by the combination of Propranolol and Perphenazine.	Schizophrenia [6A20]	[36]
Molindone	DMAH70G	Moderate	Additive hypotensive effects by the combination of Propranolol and Molindone.	Schizophrenia [6A20]	[36]
Thiothixene	DMDINC4	Minor	Increased plasma concentrations of Propranolol and Thiothixene due to competitive inhibition of the same metabolic pathway.	Schizophrenia [6A20]	[77]
Trifluoperazine	DMKBYWI	Moderate	Additive hypotensive effects by the combination of Propranolol and Trifluoperazine.	Schizophrenia [6A20]	[36]
Risperidone	DMN6DXL	Moderate	Additive hypotensive effects by the combination of Propranolol and Risperidone.	Schizophrenia [6A20]	[36]
Amisulpride	DMSJVAM	Moderate	Increased risk of ventricular arrhythmias by the combination of Propranolol and Amisulpride.	Schizophrenia [6A20]	[29]
Asenapine	DMSQZE2	Moderate	Additive hypotensive effects by the combination of Propranolol and Asenapine.	Schizophrenia [6A20]	[36]
Armodafinil	DMGB035	Moderate	Decreased metabolism of Propranolol caused by Armodafinil mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[30]
Pipecuronium	DM5F84A	Moderate	Additive neuromuscular blocking effects by the combination of Propranolol and Pipecuronium.	Tonus and reflex abnormality [MB47]	[37]
Doxacurium	DMKE7L9	Moderate	Additive neuromuscular blocking effects by the combination of Propranolol and Doxacurium.	Tonus and reflex abnormality [MB47]	[37]
Vecuronium	DMP0UK2	Moderate	Additive neuromuscular blocking effects by the combination of Propranolol and Vecuronium.	Tonus and reflex abnormality [MB47]	[37]
Rocuronium	DMY9BMK	Moderate	Additive neuromuscular blocking effects by the combination of Propranolol and Rocuronium.	Tonus and reflex abnormality [MB47]	[37]
Atropine	DMEN6X7	Moderate	Antagonize the effect of Propranolol when combined with Atropine.	Unspecific substance harmful effect [NE6Z]	[29]
Methdilazine	DMAUHQX	Moderate	Additive hypotensive effects by the combination of Propranolol and Methdilazine.	Vasomotor/allergic rhinitis [CA08]	[36]
Trimeprazine	DMEMV9D	Moderate	Additive hypotensive effects by the combination of Propranolol and Trimeprazine.	Vasomotor/allergic rhinitis [CA08]	[78]
Propafenone	DMPIBJK	Moderate	Decreased metabolism of Propranolol caused by Propafenone mediated inhibition of CYP450 enzyme.	Ventricular tachyarrhythmia [BC71]	[79]
Amiodarone	DMUTEX3	Moderate	Increased risk of atrioventricular block by the combination of Propranolol and Amiodarone.	Ventricular tachyarrhythmia [BC71]	[80]
-----------


⏷ Show the Full List of 124 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Allura red AC dye	E00338	33258	Colorant
D&C red no. 28	E00491	6097185	Colorant
D&C red no. 30	E00456	3000709	Colorant
Diethyl phthalate	E00135	6781	Plasticizing agent; Solvent
FD&C blue no. 1	E00263	19700	Colorant
FD&C blue no. 2	E00446	2723854	Colorant
Quinoline yellow WS	E00309	24671	Colorant
Sodium lauryl sulfate	E00464	3423265	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Stearic acid	E00079	5281	Emulsifying agent; Solubilizing agent; Viscosity-controlling agent; lubricant
Sunset yellow FCF	E00255	17730	Colorant
Ammonia	E00007	222	Alkalizing agent
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Carmellose sodium	E00625	Not Available	Disintegrant
Dibutyl sebacate	E00160	7986	Plasticizing agent
Diglycol stearate	E00154	7788	Emulsifying agent; Opacifying agent
Eisenoxyd	E00585	56841934	Colorant
FD&C red no. 3	E00629	Not Available	Colorant
Ferric hydroxide oxide yellow	E00539	23320441	Colorant
Ferrosoferric oxide	E00231	14789	Colorant
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Polyethylene glycol 400	E00653	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Potassium hydroxide	E00233	14797	Alkalizing agent
Povidone	E00667	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Propylene glycol	E00040	1030	Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Saccharose	E00091	5988	Binding agent; Coating agent; Cryoprotectant; Diluent; Flavoring agent; Suspending agent; Viscosity-controlling agent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Talc	E00520	16211421	Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Vinylpyrrolidone	E00668	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
--------------------


⏷ Show the Full List of 30 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Propranolol 10 mg tablet	10 mg	Oral Tablet	Oral
Propranolol 20 mg tablet	20 mg	Oral Tablet	Oral
Propranolol 40 mg tablet	40 mg	Oral Tablet	Oral
Propranolol 80 mg tablet	80 mg	Oral Tablet	Oral
Propranolol 60 mg tablet	60 mg	Oral Tablet	Oral
Propranolol 160 mg capsule	160 mg	24 HR Extended Release Oral Capsule	Oral
Propranolol 120 mg capsule	120 mg	24 HR Extended Release Oral Capsule	Oral
Propranolol 80 mg capsule	80 mg	24 HR Extended Release Oral Capsule	Oral
Propranolol 60 mg capsule	60 mg	24 HR Extended Release Oral Capsule	Oral
Propranolol 120 mg capsule	120 mg	24 HR Extended Release Capsule	Oral
Propranolol 160 mg capsule	160 mg	24 HR Extended Release Capsule	Oral
Propranolol 60 mg capsule	60 mg	24 HR Extended Release Capsule	Oral
Propranolol 80 mg capsule	80 mg	24 HR Extended Release Capsule	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	Propranolol FDA Label
2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7596).
3	Chidsey CA, Morselli P, Bianchetti G, Morganti A, Leonetti G, Zanchetti A: Studies of the absorption and removal of propranolol in hypertensive patients during therapy. Circulation. 1975 Aug;52(2):313-8. doi: 10.1161/01.cir.52.2.313.
4	BDDCS applied to over 900 drugs
5	FDA Approved Drug Products: HEMANGEOL (propranolol hydrochloride) oral solution
6	Walle T, Walle UK, Olanoff LS: Quantitative account of propranolol metabolism in urine of normal man. Drug Metab Dispos. 1985 Mar-Apr;13(2):204-9.
7	FDA Approved Drug Products: INNOPRAN XL (propranolol hydrochloride) extended release capsules
8	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
9	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
10	ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
11	Beta-blockers in the treatment of hypertension: are there clinically relevant differences Postgrad Med. 2009 May;121(3):90-8.
12	Influx Transport of Cationic Drug at the Blood-Retinal Barrier: Impact on the Retinal Delivery of Neuroprotectants. Biol Pharm Bull. 2017;40(8):1139-1145.
13	Tarascon Pocket Pharmacopoeia 2018 Classic Shirt-Pocket Edition.
14	Cytochrome P450 isozymes involved in propranolol metabolism in human liver microsomes. The role of CYP2D6 as ring-hydroxylase and CYP1A2 as N-desisopropylase. Drug Metab Dispos. 1994 Nov-Dec;22(6):909-15.
15	Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
16	Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br J Clin Pharmacol. 2001 Oct;52(4):349-55.
17	Synthetic and natural compounds that interact with human cytochrome P450 1A2 and implications in drug development. Curr Med Chem. 2009;16(31):4066-218.
18	The influence of diltiazem versus cimetidine on propranolol metabolism. J Clin Pharmacol. 1992 Dec;32(12):1099-104.
19	Human FMO2-based microbial whole-cell catalysts for drug metabolite synthesis. Microb Cell Fact. 2015 Jun 12;14:82.
20	acillus megaterium SF185 spores exert protective effects against oxidative stress in vivo and in vitro. Sci Rep. 2019 Aug 19;9(1):12082.
21	beta2-adrenergic antagonists suppress pancreatic cancer cell invasion by inhibiting CREB, NFB and AP-1. Cancer Biol Ther. 2010 Jul 1;10(1):19-29.
22	An effector domain mutant of Arf6 implicates phospholipase D in endosomal membrane recycling. Mol Biol Cell. 2006 Jan;17(1):327-35. doi: 10.1091/mbc.e05-06-0523. Epub 2005 Nov 9.
23	Propranolol inhibits proliferation and induces apoptosis of hemangioma-derived endothelial cells via Akt pathway by down-regulating Ang-2 expression. Chem Biol Interact. 2020 Jan 25;316:108925. doi: 10.1016/j.cbi.2019.108925. Epub 2019 Dec 12.
24	Labetalol (AH5158), a competitive alpha- and beta-receptor blocking drug, in the management of hypertension. Aust N Z J Med. 1976 Aug;6(3 Suppl):83-8. doi: 10.1111/j.1445-5994.1976.tb03341.x.
25	Rapid induction of P-glycoprotein expression by high permeability compounds in colonic cells in vitro: a possible source of transporter mediated drug interactions?. Biochem Pharmacol. 2004 Aug 15;68(4):783-90. doi: 10.1016/j.bcp.2004.05.006.
26	Expression of inwardly rectifying potassium channels (GIRKs) and beta-adrenergic regulation of breast cancer cell lines. BMC Cancer. 2004 Dec 16;4:93. doi: 10.1186/1471-2407-4-93.
27	Reciprocal in vivo regulation of myocardial G protein-coupled receptor kinase expression by beta-adrenergic receptor stimulation and blockade. Circulation. 1998 Oct 27;98(17):1783-9. doi: 10.1161/01.cir.98.17.1783.
28	Goldberg MR, Sciberras D, De Smet M, et al. "Influence of B-adrenoceptor antagonists on the ppharmacokinetics of rizatriptan, a 5-HT IB/ID agonist: differential effects of propranolol, nadolol and metoprolol." Br J Clin Pharmacol 52 (2001): 69-76. [PMID: 11453892]
29	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
30	Cerner Multum, Inc. "Australian Product Information.".
31	Anastassiades CJ "Nifedipine and beta-blocker drugs." Br Med J 281 (1980): 1251-2. [PMID: 6107167]
32	Haglund K, Seideman P, Colliste P, Borg KO, von Bahr C "Influence of pentobarbital on metoprolol plasma levels." Clin Pharmacol Ther 26 (1979): 326-9. [PMID: 466926]
33	Hawksworth G, Betts T, Crowe A, et al "Diazepam/beta-adrenoceptor antagonist interactions." Br J Clin Pharmacol 17 Suppl 1 (1984): s69-76. [PMID: 6146341]
34	Product Information. Zylo Filmtab (zileuton). Abbott Pharmaceutical, Abbott Park, IL.
35	Product Information. Ocaliva (obeticholic acid). Intercept Pharmaceuticals, Inc., New York, NY.
36	Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30. [PMID: 7884028]
37	Chapple DJ, Clark JS, Hughes R "Interaction between atracurium and drugs used in anaesthesia." Br J Anaesth 55 Suppl 1 (1983): s17-22. [PMID: 6688011]
38	Canadian Pharmacists Association.
39	Product Information. Isturisa (osilodrostat). Recordati Rare Diseases Inc, Lebanon, NJ.
40	Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
41	Amchin J, Ereshefsky L, Zarycranski W, Taylor K, Albano D, Klockowski PM "Effect of venlafaxine versus fluoxetine on metabolism of dextromethorphan, a CYP2D6 probe." J Clin Pharmacol 41 (2001): 443-51. [PMID: 11304901]
42	Saiz-Ruiz J, Moral L "Delirium induced by association of propranolol." J Clin Psychopharmacol 8 (1988): 77-8. [PMID: 3351011]
43	Branch RA, Herman RJ "Enzyme induction and beta-adrenergic receptor blocking drugs." Br J Clin Pharmacol 17 (1984): s77-84. [PMID: 6146342]
44	Product Information. Xcopri (cenobamate). SK Life Science, Inc., Paramus, NJ.
45	EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
46	Dean S, Kendall MJ, Potter S, Thompson MH, Jackson DA "Nadolol in combination with indapamide and xipamide in resistant hypertensives." Eur J Clin Pharmacol 28 (1985): 29-33. [PMID: 3987783]
47	Chrysant SG "Experience with terazosin administered in combination with other antihypertensive agents." Am J Med 80 (1986): 55-61. [PMID: 2872808]
48	Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
49	AbdelRahman SM, Gotschall RR, Kauffman RE, Leeder JS, Kearns GL "Investigation of terbinafine as a CYP2D6 inhibitor in vivo." Clin Pharmacol Ther 65 (1999): 465-72. [PMID: 10340911]
50	Kirch W, Rose I, Klingmann I, Pabst J, Ohnhaus EE "Interaction of bisoprolol with cimetidine and rifampicin." Eur J Clin Pharmacol 31 (1986): 59-62. [PMID: 2877885]
51	Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov). Gilead Sciences, Foster City, CA.
52	Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
53	Amemiya M, Tabei K, Furuya H, Sakairi Y, Asano Y "Pharmacokinetics of carteolol in patients with impaired renal function." Eur J Clin Pharmacol 43 (1992): 417-21. [PMID: 1451723]
54	Product Information. Givlaari (givosiran). Alnylam Pharmaceuticals, Cambridge, MA.
55	Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
56	Product Information. Vizimpro (dacomitinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
57	Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
58	Product Information. Tabrecta (capmatinib). Novartis Pharmaceuticals, East Hanover, NJ.
59	Lancaster DL, Adio RA, Tai KK, Simooya OO, Broadhead GD, Tucker GT, Lennard MS "Inhibition of metoprolol metabolism by chloroquine and other antimalarial drugs." J Pharm Pharmacol 42 (1990): 267-71. [PMID: 1974295]
60	Product Information. Zelboraf (vemurafenib). Genentech, South San Francisco, CA.
61	Product Information. Betapace (sotalol). Berlex, Richmond, CA.
62	Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
63	Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
64	Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
65	Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ.
66	Product Information. Gleevec (imatinib mesylate). Novartis Pharmaceuticals, East Hanover, NJ.
67	Product Information. Varubi (rolapitant). Tesaro Inc., Waltham, MA.
68	Dufresne RL, Weber SS, Becker RE "Bupropion hydrochloride." Drug Intell Clin Pharm 18 (1984): 957-64. [PMID: 6439541]
69	Product Information. Belviq (lorcaserin). Eisai Inc, Teaneck, NJ.
70	EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
71	Janku I, Perlik F, Tkaczykova M, Brodanova M "Disposition kinetics and concentration-effect relationship of metipranolol in patients with cirrhosis and healthy subjects." Eur J Clin Pharmacol 42 (1992): 337-40. [PMID: 1349528]
72	Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
73	Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
74	Product Information. Zytiga (abiraterone). Centocor Inc, Malvern, PA.
75	Benoist G, van Oort I, et al "Drug-drug interaction potential in men treated with enzalutamide: Mind the gap." Br J Clin Pharmacol 0 (2017): epub. [PMID: 28881501]
76	Abernethy DR, Greenblatt DJ, Steel K, Shader RI "Impairment of hepatic drug oxidation by propoxyphene." Ann Intern Med 97 (1982): 223-4. [PMID: 7103282]
77	Ereshefsky L, Saklad SR, Watanabe MD, Davis CM, Jann MW "Thiothixene pharmacokinetic interactions: a study of hepatic enzyme inducers, clearance inhibitors, and demographic variables." J Clin Psychopharmacol 11 (1991): 296-301. [PMID: 1765572]
78	Product Information. Clozaril (clozapine). Novartis Pharmaceuticals, East Hanover, NJ.
79	Ahmad S "Metoprolol-induced delirium perpetuated by propafenone." Am Fam Physician 44 (1991): 1142,4. [PMID: 1927831]
80	Leor J, Levartowsky D, Sharon C, Farfel Z "Amiodarone and beta-adrenergic blockers: an interaction with metoprolol but not with atenolol." Am Heart J 16 (1988): 206-7. [PMID: 3394625]